Phase I dose-escalation and pharmacokinetic study of a novel folate analogue AG2034
Open Access
- 5 February 2001
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 84 (3) , 308-312
- https://doi.org/10.1054/bjoc.2000.1601
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Pharmacokinetic and pharmacodynamic evaluation of the glycinamide ribonucleotide formyltransferase inhibitor AG2034.2000
- Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeksCancer Chemotherapy and Pharmacology, 2000
- Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.1998
- Phase I study of the antipurine antifolate lometrexol (DDATHF) with folinic acid rescue.1996
- Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement.1995
- Phase I Study of (6R)-5, 10-Dideazatetrahydrofolate: a Folate Antimetabolite Inhibitory to De Novo Purine SynthesisJNCI Journal of the National Cancer Institute, 1993
- A program package for simulation and parameter estimation in pharmacokinetic systemsComputer Programs in Biomedicine, 1979